ALK-Abello Overview
- Year Founded
-
1923
- Status
-
Public
- Employees
-
2,759
- Stock Symbol
-
ALK B
- Investments
-
12
- Share Price
-
$35.96
- (As of Thursday Closing)
ALK-Abello General Information
Description
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Contact Information
Website
www.alk.netCorporate Office
- Boge Alle 6-8
- 2970 Horsholm
- Denmark
Corporate Office
- Boge Alle 6-8
- 2970 Horsholm
- Denmark
ALK-Abello Stock Performance
As of 19-Nov-2026, ALK-Abello’s stock price is $35.96. Its current market cap is $7.98B with 222M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $35.96 | $35.74 | $29.41 - $42.20 | $7.98B | 222M | 231K | $0.98 |
ALK-Abello Financials Summary
As of 30-Sep-2026, ALK-Abello has a trailing 12-month revenue of $1.1B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,478,621 | 7,948,712 | 4,918,226 | 3,399,317 |
| Revenue | 1,098,175 | 953,652 | 803,170 | 700,048 |
| EBITDA | 343,151 | 302,775 | 199,886 | 137,572 |
| Net Income | 218,298 | 180,849 | 118,220 | 70,527 |
| Total Assets | 1,554,924 | 1,424,303 | 1,150,455 | 998,622 |
| Total Debt | 72,513 | 65,735 | 165,606 | 113,581 |
ALK-Abello Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ALK-Abello Signals
ALK-Abello Investments & Acquisitions (12)
ALK-Abello’s most recent deal was a Seed Round with Allegria Therapeutics for . The deal was made on 11-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Allegria Therapeutics | 11-Dec-2025 | Seed Round | Other Pharmaceuticals and Biotechnology | ||
| Allerquest | 02-Jan-2024 | Merger/Acquisition | Clinics/Outpatient Services | ||
| Otonomy (Otiprio Fluoroquinolone Antibacterial) | 28-May-2021 | Corporate Asset Purchase | Pharmaceuticals | ||
| Betamab Therapeutics | 20-Apr-2020 | Corporate | Drug Delivery | ||
| Allergy Laboratories | 03-Jan-2017 | Merger/Acquisition | Pharmaceuticals |
ALK-Abello ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
25.89 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
ALK-Abello Exits (3)
ALK-Abello’s most recent exit was on 12-Feb-2014 from Actt. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Actt | 12-Feb-2014 | Completed |
|
||
| DBV Technologies | 05-Jan-2011 | Completed |
|
||
| DBV Technologies | 21-Jan-2009 | Later Stage VC | Completed |
|
ALK-Abello Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Alk-Abelló Nordic | Hoersholm, Denmark | 2008 | |
| Allerquest | Monroe, CT | 2005 | |
| Nelco Vet | New York, NY | 2001 | |
| Alk-Abello' Source Materials | Post Falls, ID | 1975 | |
| Western Allergy Services | Victoria, Canada | 1972 |
ALK-Abello FAQs
-
When was ALK-Abello founded?
ALK-Abello was founded in 1923.
-
Where is ALK-Abello headquartered?
ALK-Abello is headquartered in Horsholm, Denmark.
-
What is the size of ALK-Abello?
ALK-Abello has 2,759 total employees.
-
What industry is ALK-Abello in?
ALK-Abello’s primary industry is Clinics/Outpatient Services.
-
Is ALK-Abello a private or public company?
ALK-Abello is a Public company.
-
What is ALK-Abello’s stock symbol?
The ticker symbol for ALK-Abello is ALK B.
-
What is the current stock price of ALK-Abello?
As of 19-Nov-2026 the stock price of ALK-Abello is $35.96.
-
What is the current market cap of ALK-Abello?
The current market capitalization of ALK-Abello is $7.98B.
-
What is ALK-Abello’s current revenue?
The trailing twelve month revenue for ALK-Abello is $1.1B.
-
What is ALK-Abello’s annual earnings per share (EPS)?
ALK-Abello’s EPS for 12 months was $0.98.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process